Loading...
OTCM
NSTM
Market cap1mUSD
Jun 06, Last price  
0.03USD
Name

Novelstem International Corp

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.66%
Rev. gr., 5y
-54.51%
Revenues
0k
-100.00%
10,100,00029,517,50550,154,80158,237,27164,858,96272,978,66795,614,439115,895,460123,881,223117,057,931103,378,9103,995,1773,769,772616,338424,7510012,00012,0000
Net income
-3m
L-22.79%
-24,700,000-51,847,500-41,829,905-81,550,116-7,441,687-11,597,799-8,913,1829,522,5131,734,609-16,856,323-5,620,4174,905,567-6,862,33110,409,5646,252,848-545,439-1,352,453-765,730-4,187,300-3,233,042
CFO
-272k
L-21.91%
-9,900,000-13,017,504-5,414,855-3,958,217-351,274-5,772,737-3,952,944-2,709,928-7,646,636-7,177,22977,9593,931,400-2,594,704-3,915,8690419,338-180,928-182,320-348,283-271,964
Dividend
Mar 22, 20180.45 USD/sh
Earnings
Aug 12, 2025

Profile

NovelStem International Corp. focuses on developing and commercialization of diagnostic technology for cancer treatments and the potential to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was founded in 1993 and is headquartered in Boca Raton, Florida.
URL
https://www.novelstem.com/
IPO date
Nov 12, 1993
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑12
Income
Revenues
12
0.00%
12
 
Cost of revenue
893
665
434
Unusual Expense (Income)
NOPBT
(893)
(653)
(422)
NOPBT Margin
Operating Taxes
161
302
332
Tax Rate
NOPAT
(1,054)
(956)
(755)
Net income
(3,233)
-22.79%
(4,187)
446.84%
(766)
-43.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
4,418
250
Long-term debt
3,325
288
Deferred revenue
Other long-term liabilities
535
Net debt
4,412
1,604
(1,945)
Cash flow
Cash from operating activities
(272)
(348)
(182)
CAPEX
Cash from investing activities
(250)
(250)
Cash from financing activities
475
645
180
FCF
(209)
(929)
(856)
Balance
Cash
6
53
6
Long term investments
1,918
2,227
Excess cash
6
1,970
2,233
Stockholders' equity
(295,892)
(292,659)
(288,472)
Invested Capital
295,166
294,817
290,693
ROIC
ROCE
122.93%
EV
Common stock shares outstanding
46,881
46,881
46,881
Price
0.01
 
0.19
-32.93%
Market cap
366
 
8,804
-28.96%
EV
4,778
6,859
EBITDA
(893)
(653)
(404)
EV/EBITDA
Interest
425
99
11
Interest/NOPBT